62 related articles for article (PubMed ID: 38646606)
1. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
[TBL] [Abstract][Full Text] [Related]
2. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
3. Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan.
Oga T; Mita C; Ito R; Requena G; Rothnie KJ; Noorduyn SG; Yuanita L; Yarita M
Respir Investig; 2024 May; 62(4):685-694. PubMed ID: 38796907
[TBL] [Abstract][Full Text] [Related]
4. Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study.
Boulet LP; Abbott C; Brusselle G; Edwards D; Oppenheimer J; Pavord ID; Pizzichini E; Sagara H; Slade D; Wechsler ME; Gibson PG
J Allergy Clin Immunol Pract; 2024 May; 12(5):1244-1253.e8. PubMed ID: 38309696
[TBL] [Abstract][Full Text] [Related]
5. Budesonide/Glycopyrrolate/Formoterol for the Management of COPD in a UK Primary Care Population: Real-World Use and Early Medication Success.
Müllerová H; Chan JSK; Heatley H; Carter V; Townend J; Skinner D; Franzén S; Marshall J; Price D
Int J Chron Obstruct Pulmon Dis; 2024; 19():1153-1166. PubMed ID: 38813078
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant.
Rony F; Cortellini M; Guasconi A; Mathews KS; Piccinno A; Poli G; Vanhoutte F; Klein J
Pulm Pharmacol Ther; 2024 Jun; 85():102299. PubMed ID: 38663512
[TBL] [Abstract][Full Text] [Related]
7. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study.
Di Marco F; Santus P; Terraneo S; Peruzzi E; Muscianisi E; Ripellino C; Pegoraro V
NPJ Prim Care Respir Med; 2017 Sep; 27(1):51. PubMed ID: 28883469
[TBL] [Abstract][Full Text] [Related]
9. The effect of inhaler prescription on the development of lung cancer in COPD: a nationwide population-based study.
Park JE; Lee E; Singh D; Kim EK; Park B; Park JH
Respir Res; 2024 May; 25(1):229. PubMed ID: 38822332
[TBL] [Abstract][Full Text] [Related]
10. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.
Singh D; Corradi M; Spinola M; Petruzzelli S; Papi A
NPJ Prim Care Respir Med; 2016 Jun; 26():16030. PubMed ID: 27309985
[TBL] [Abstract][Full Text] [Related]
11. The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada - the IMPACT trial.
Risebrough NA; Mursleen S; Ndirangu K; Shah D; Martin A; Schroeder M; Ismaila AS
Respir Med; 2024 Jun; ():107694. PubMed ID: 38844004
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors Associated with Misuse of Soft Mist Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
Jang JG; Lee YS; Hong KS; Ahn JH
Int J Chron Obstruct Pulmon Dis; 2024; 19():1225-1232. PubMed ID: 38835808
[TBL] [Abstract][Full Text] [Related]
13. Risk of pharmacological treatment of anxiety and depression after admission for acute exacerbation of chronic obstructive pulmonary disease.
Hermann Karlsen J; Jacobsen PA; Kragholm K; Torp-Pedersen C; Nielsen LB; Weinreich UM
Respir Med; 2024 May; 229():107680. PubMed ID: 38815658
[TBL] [Abstract][Full Text] [Related]
14. Readability and Suitability of COPD Consumer Information.
Fullmann K; Blackburn DF; Fenton ME; Mansell H
Can Respir J; 2017; 2017():2945282. PubMed ID: 28947874
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
Beeh KM; Rothnie KJ; Claussen J; Hardtstock F; Knapp RK; Wilke T; Czira A; Compton C; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2024; 19():945-956. PubMed ID: 38646606
[TBL] [Abstract][Full Text] [Related]
16. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England.
Rothnie KJ; Joksaite S; Sansbury LB; Compton C; Di Boscio V; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2022; 17():1455-1466. PubMed ID: 35769225
[TBL] [Abstract][Full Text] [Related]
18. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
[TBL] [Abstract][Full Text] [Related]
19. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
